|
Lymphangioleiomyomatosis (LAM) Registry Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Lymphangioleiomyomatosis (LAM) Registry conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Lymphangioleiomyomatosis (LAM) Registry Clinical research trials and Lymphangioleiomyomatosis (LAM) Registry healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Lymphangioleiomyomatosis (LAM) Registry. Lymphangioleiomyomatosis (LAM) Registry Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Lymphangioleiomyomatosis (LAM) Registry clinical trial. Human subjects often obtain the finest healthcare possible for their Lymphangioleiomyomatosis (LAM) Registry condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Lymphangioleiomyomatosis (LAM) Registry  Lymphangioleiomyomatosis (LAM) Registry
Lymphangioleiomyomatosis (LAM) Registry
For Condition: Lymphangiomyomatosis,Lung Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To establish a registry of individuals with LAM by forming a consortium of six clinical centers and referring physicians who treat LAM patients.
Details: BACKGROUND: LAM is a rare multi-system disease that can affect the lungs of young women, is of uncertain cause, is usually progressive, and can cause debilitating lung disease which may be corrected with lung transplantation. Several hundred women with the disease have been identified, largely through a LAM Foundation in Cincinnati, Ohio. DESIGN NARRATIVE: The Data and Coordinating Center is located at the Cleveland Clinic Foundation. The registry has six major clinical centers: Cleveland Clinic Foundation, Mayo Clinic-Rochester, National Heart, Lung, and Blood Institute, National Jewish Medical and Research Center, New England Medical Center, and Stanford University Medical Center. Data and lung tissue collected by the registry will be used to characterize the clinical features and natural history of the disease and to determine the efficacy of lung transplantation in this disorder. Eligible patients are to be seen yearly for up to 4 years at the Clinical Centers or, in some cases, by individual referring physicians. Tissue collected by the LAM Registry will be stored at a central NHLBI repository. Outcome events include measures of pulmonary function (eg, spirometry and, when available, lung volumes and diffusing capacity), arterial blood gases or oximetry, walking and resting oxygen titration, cardiopulmonary stress testing, cause-specific mortality, functional status, and clinical events associated with lung transplantation. The Office of Research on Women's Health provided funding in FY 1997 in the amount of $100,000.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GeraldBeck, , Cleveland Clinic Foundation Hospital
Additional Information:
Study ID Numbers: 5002;
Study Start Date: July 1997
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005486
Other Lung Diseases Studies:
1. Treatment with Octreotide in Patients with Lymphangioleiomyomatosis
2. Lymphangioleiomyomatosis (LAM) Registry
Related Studies:
Other Lung Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Lymphangioleiomyomatosis (LAM) Registry
|
|
|
|
|
|
|
|
